Quantitative assessment of cerebral glucose consumption rate (CMR glc ) and tricarboxylic acid cycle flux (V TCA ) is crucial for understanding neuroenergetics under physiopathological conditions. In this study, we report a novel in vivo Deuterium ( 2 H) MRS (DMRS) approach for simultaneously measuring and quantifying CMR glc and V TCA in rat brains at 16.4 Tesla. Following a brief infusion of deuterated glucose, dynamic changes of isotope-labeled glucose, glutamate/ glutamine (Glx) and water contents in the brain can be robustly monitored from their well-resolved 2 H resonances. Dynamic DMRS glucose and Glx data were employed to determine CMR glc and V TCA concurrently. To test the sensitivity of this method in response to altered glucose metabolism, two brain conditions with different anesthetics were investigated. Increased CMR glc (0.46 vs. 0.28 mmol/g/min) and V TCA (0.96 vs. 0.6 mmol/g/min) were found in rats under morphine as compared to deeper anesthesia using 2% isoflurane. This study demonstrates the feasibility and new utility of the in vivo DMRS approach to assess cerebral glucose metabolic rates at high/ultrahigh field. It provides an alternative MRS tool for in vivo study of metabolic coupling relationship between aerobic and anaerobic glucose metabolisms in brain under physiopathological states.
Introduction
Cerebral glucose metabolism is of importance for brain function since glucose is the major fuel for energy production in the form of ATP, which is essential to maintain electrophysiological activity for neuronal firing, signaling and cellular functionality. Quantitative assessment of cerebral glucose consumption rate (CMR glc ) and the associated major metabolic fluxes, such as the TCA cycle flux (V TCA ), a-ketoglutarate/glutamate exchange and oxygen consumption rates, is crucial for understanding neuroenergetics under various physiological and pathological conditions. However, simultaneous measurement of both CMR glc and V TCA has been challenging due to the complexity of brain glucose metabolisms and limitations of current technology.
For decades, in vivo 13 C MRS in combination with 13 C-labeled substrate infusion has been the unique tool to investigate brain metabolic fluxes (e.g. V TCA ) and neurotransmission cycling rates noninvasively by analyzing 13 C-labeled glutamate time courses using 13 C-labeled glucose or acetate infusion and complex metabolic modeling. [1] [2] [3] [4] [5] [6] To date, despite of its extensive use, it remains a challenging technique owing to relatively low MR sensitivity and the requirement of 13 C-1 H dual channels, 1 H NOE preparation and decoupling. In addition, except for a small number of studies using 13 C-labeled glucose signal for modeling glucose transport, 7 the majority of 13 C MRS studies do not utilize the 13 C-labeled glucose signal, the CMR glc measurement is indirectly estimated based on an assumed coupling relationship between glycolysis and the measured V TCA . 4, 5 Nevertheless, such relationship could change substantially or become decoupled in diseased tissues, e.g. in brain tumor and stroke.
Another gold-standard imaging modality for regional CMR glc assessment has been the 18 F-fluorodeoxyglucose ( 18 FDG)-PET imaging method established since 1980s. [8] [9] [10] [11] It has been widely used not only in animal but also in human brains under normal or diseased conditions, [12] [13] [14] [15] [16] [17] [18] [19] though it requires administration of radioactive agent. Since the 18 FDG-PET can only measure the 18 FDG uptake in the cytosol, it is incapable of providing mitochondrial oxidative metabolic information including V TCA . Therefore, to obtain both CMR glc and V TCA for comprehensive evaluation of cerebral glucose metabolisms, researchers commonly perform 18 FDG-PET and in vivo 13 C MRS measurements separately using two imaging modalities. It is critical to exploit emerging metabolic imaging methods for undertaking the technical challenge.
Deuterium ( 2 H) contains one proton and one neutron, and it is a stable and non-radioactive isotope of hydrogen with spin quantum number of 1 (thus, dominated by quadrupolar relaxation mechanism) and a low natural abundance of 0.0156% on earth. Having a similar range of chemical shift (in ppm) to proton NMR, 2 H NMR spectra are popular in the solid state NMR research to study lipid membrane, protein and peptide structure or dynamics due to its relatively small quadrupole moment. 20 High-resolution 2 H NMR has been applied in elucidating metabolic pathways in gluconeogenesis through plasma samples 21 and in fermentation. 22, 23 However, except the first preliminary attempt by Mateescu et al., 24 there has been no other in vivo deuterium magnetic resonance (DMR) spectroscopy (DMRS) study reported that investigates glucose metabolism and mitochondrial respiration. The advantage of in vivo DMRS becomes obvious when combining with 2 H-isotope labeled glucose infusion, which results from its excellent chemical specificity and informative dynamic spectra in that labeling of the substrate, i.e. glucose, and intermediate metabolites through glycolysis and oxidative phosphorylation pathways can be distinguished, especially at high/ultrahigh field. These merits allow for the possibility of isotope kinetic analysis and eventually for quantification of glucose metabolisms. Thus, in view of the benefits it can bring, a well-developed quantitative in vivo DMRS approach is highly desirable.
In this study, a novel in vivo DMRS approach that enables simultaneous measurement of CMR glc and V TCA is proposed and examined in rat brain at 16.4 Tesla (T). Briefly, following a brief intravenous infusion of deuterated glucose, the dynamic labeling of glucose, glutamate/glutamine (Glx) and water in the brain tissue can be monitored using their well-resolved resonance signals in dynamic 2 H spectra with excellent sensitivity and temporal resolution, which can be attributed to the very short longitudinal relaxation time (T 1 ) of 2 Hlabeled molecules as compared to that of 1 H or 13 C spins, thus, allowing more signal averaging within the same sampling time. A new kinetic model incorporating glycolysis, TCA cycle and a-ketoglutarate/Glx exchange is then developed. By least-square fittings of the model with the dynamic DMRS glucose and Glx data, CMR glc and V TCA can be concurrently determined. The sensitivity and reliability of this approach in assessing cerebral glucose metabolism and its change are also evaluated in this work by using two different brain conditions: 2% isoflurane (deep anesthesia) vs. morphine infusion (analgesia).
Materials and methods

Animal preparation and experimental protocol
Eight male Sprague Dawley rats (body weight: 350 AE 47 g) were anesthetized with 2% isoflurane in a mixture of O 2 and N 2 O gases ($2:3) and prepared for in vivo DMRS scans. The rat femoral arteries and veins were catheterized for blood sampling, physiological monitoring, deuterated glucose and/or morphine infusion. Rectal temperature was maintained at 37 AE 1 C using heated circulating water. Blood gases were sampled for monitoring physiological conditions. The arterial blood pressure and heart rate were monitored during the entire experiment. The end-tidal CO 2 was monitored (Capnomac Ultima; Finland) and maintained at normal levels (3-4%). The animals were maintained under physiological conditions throughout the measurements. The animal procedures and experiments were conducted in accordance with the National Research Council' s Guide for the Care and Use of Laboratory Animals and under the protocols approved by the Institutional Animal Care and Use Committee of University of Minnesota, and were compliance with the ARRIVE guidelines (Animal Research: Reporting in Vivo Experiments).
For each rat, after surgical preparation and a waiting period ($1 h) for stabilizing animal physiological condition inside the 16.4 T magnet, 10-min baseline 2 H spectra (described in the following section) were acquired that followed by 2 min intravenous infusion of D-Glucose-6,6-d 2 (d66, Sigma-Aldrich; 1.3 g/kg body weight and dissolved in 2.5 mL saline) and 120 min continuous DMRS acquisitions (see the experimental protocol as shown in Figure S1 ). Multiple arterial blood samples were drawn during the DMRS experiment for assessing the dynamics of blood ( 2 H-labeled and non-labeled) glucose levels.
To test the sensitivity of in vivo DMRS method in response to altered metabolic activity, four of the eight rats were switched from deep anesthesia condition using 2% isoflurane to analgesia condition with constant infusion of morphine sulfate (West-Ward, NJ; 25 mg/kg/h), which was started before the onset of baseline DMRS acquisitions. Figure S1 displays the schematic diagram of the experimental protocol used in this study.
Deuterium MR spectroscopy and metabolites quantification
All in vivo MR experiments were conducted at 16.4 T/26 cm horizontal scanner (Varian/VNMRJ, CA) using a passively decoupled radio frequency (RF) dual-coil probe, which includes an oval-shaped singleloop 2 H surface coil (10 mm Â 20 mm) for DMRS acquisition and a butterfly-shaped 1 H surface coil for shimming and anatomical images. The 2 H RF probe was placed over the rat head between the eyes and ears and tuned to 107 MHz for acquiring the 2 H MRS data. The 2 H RF coil size and RF pulse flip angle were optimized to maximize the 2 H signals from the rat brain; nevertheless, the partial signal contribution from the surrounding muscle was still inevitable. A single-pulse-acquire sequence was applied to obtain dynamic DMR spectra from the rat brain with the following parameters: 3 kHz spectral width, 512 points for each free induction decay (FID), 0.3 s repetition time with 50 averages (15 s per spectrum) and a total of 520 spectra (130 min in total). Raw FID signals were converted into frequency domain spectra by Fourier transformation using an exponential filter with 13 Hz to enhance the signal-to-noise ratio (SNR).
A spherical phantom containing 5 mM of d66 dissolved in saline solution was also prepared for identifying and assigning the chemical shifts of water (set at 4.8 ppm as a reference) and glucose resonance peaks in DMR spectrum and validating quantification accuracy of metabolites.
All 2 H resonance signal integrals (except for the weak lactate resonance signal observed in the healthy rat brain) were fitted using a MATLAB-based program for quantification. The concentrations of deuterated glucose (d66) and labeled Glx in the brain tissue or phantom solution were quantified by normalizing their fitted resonance integrals to that of the baseline water signal, which has the natural abundance 2 H concentration of 17.2 mM in water phantom (¼55 Â 2 Â 0.0156% in considering 55 M water concentration and 0.0156% deuterium natural abundance) and 13.7 mM for brain tissue water in considering the water content fraction of 0.8 in the brain tissue. 25, 26 The T 1 values of deuterated water, Glx and d66 were measured in rat brains at 16.4 T using the inversionrecovery method under fully relaxed condition with a long pre-inversion delay of 2 s and 16 signal averages. To compensate the RF magnetic field (B 1 ) inhomogeneity of the 2 H surface coil and its implication on the T 1 measurement, a B 1 -insensitive hyperbolic secant inversion pulse 27 was used followed by magnetization dephasing gradients. Each T 1 value was determined by a three-parameter least-square fitting of a single exponential function to the resonance signals with a total of 10 different inversion-recovery times (0.012-12 s). For comparison, T 1 values of deuterated water and d66 in the phantom solution were also measured. Blood glucose concentration (labeled plus non-labeled ones) was measured with glucose meter (ACCU-CHEK, Roche). Plasma-labeled glucose level was quantified by analyzing high-resolution 2 H NMR spectrum obtained at 11.7 T (Varian Inova-500 with 5 mm Broadband probe tuned to 2 H frequency) using the standard d66 (20 mM) solution as an internal reference. The results were used to determine the glucose fraction of 2 H enrichment (FE) and its dynamic change. Figure S2 demonstrates the representative results from one rat study. Figure 1 shows the 2 H-isotope labeling scheme detectable by dynamic DMRS in the brain tissue after d66 infusion and the associated metabolic pathways. Following the infusion, d66 glucose is transported together with non-labeled glucose into the brain and metabolized through glycolysis and oxidative phosphorylation pathways. Dynamics of the cerebral d66 and incorporation of the label into the pools of lactate, glutamate and water could be detected by sequential DMRS acquisitions with adequate SNR in each spectrum. Similar to 13 C MRS, the 2 H NMR signal of glutamate is the result from its relatively high labeling concentration of intracellular glutamate that is in constant exchange with the TCA cycle via a-ketoglutarate ( Figure 1 ). Since it is difficult to resolve the resonances of glutamate and glutamine (labeled through glutamate/glutamine cycle) in the DMR spectrum, Glx served as a combined pool of them in this study. In contrast to 13 C MRS, in vivo DMRS can also provide new information for assessing 2 H labeling dynamics of brain tissue water ( Figure 1 ).
Kinetic model and analysis
Analysis of metabolic activity and kinetics is based on the pre-steady state DMR spectra of glucose and Glx reflecting their 2 H labeling dynamics. A new and simplified kinetic model incorporating glycolysis, TCA cycle and a-ketoglutarate/Glx exchange was developed. As shown in Figure 2 , five cerebral metabolites plus the blood glucose were involved in this lumped model.
Both of the changes in blood glucose level and plasma 2 H-labeled glucose concentration during the post-deuterated glucose infusion period (note that the time point of 5 min after infusion ending was set to zero for performing the kinetic analysis and model regression) were fitted based on exponential decay functions, which were then served as model inputs for further kinetic analysis and quantification.
Ten differential equations (see below) from all five metabolite pools in the brain tissue (two equations for each metabolite: one for total, i.e., non-labeled plus labeled; the other one for labeled only) constituted the mathematical model. By least-square fittings of the model outputs with the time course of 2 H labeled brain glucose and Glx concentrations, major metabolic fluxes of CMR glc and V TCA and the glycogen synthetic rate (V y ) were determined.
Mass and isotope balance equations describing the metabolic model (a) Brain glucose [Glc] brain (labeled plus non-labeled; unit: mM, converted to mmol/g brain tissue by assuming the brain tissue density of 1.1 g/ml)
where K T : half-saturation constant (mM); T max : maximum transport rate (mM/min); [Glc] blood : blood glucose level (labeled plus non-labeled, mM); CMR glc : cerebral metabolic rate of glucose (mM/min, converted to mmol/g brain tissue/min by assuming the brain tissue density of 1.1 g/ml).
(b) Brain labeled glucose * [Glc] brain (unit: mM, converted to mmol/g brain tissue by assuming the brain tissue density of 1.1 g/ml) 
where V out : an efflux of lactate. 
(f) Brain glycogen, [Gly] and * [Gly]
The following parameters of pool sizes and rates were taken from different reports in the literature: 29 [K] ¼ 0.12 mM; 29 [Glx] ¼ 20 mM; 4,5,29 [Gly] ¼ 5.3 mM; 30,31 V out ¼ 0.13 mM/min. 4 Other parameters of T max (¼3.1 AE 0.2 mmol/g/min), K T (¼6.4 AE 4.4 mmol/g) and V x (¼4.2 AE 3.3 mmol/g/ min) were determined by kinetic analysis in the present study. By using variance and the Jacobian matrix, the covariance of CMR glc and V TCA was calculated (¼0.013). The impact of V out variation on the modeling was examined. Within a reasonable range of the change in V out (0.13 AE 10%, e.g. þ8% reported in the literature 32 ), the maximal estimated changes in CMR glc and V TCA were within 4% under the anesthesia condition as employed in the present study. Therefore, small variation in V out should not impact the CMR glc and V TCA measurements significantly. In addition, our simulation indicated that the influence of the 2 H-labeled glucose in blood on the outcome of regressed brain metabolic rates was negligible owing to a small fraction of blood volume in brain tissue and rapid decay of the labeled glucose concentration in the blood during the post-infusion period.
All results were presented as mean AE standard deviation (SD). Comparisons were performed using Student's t-test with the differences in mean values considered to be statistically significant at a probability level of p < 0.05. Figure 3 demonstrates excellent spectral quality and good fittings of the original spectra not only for the 2 H spectrum of phantom solution but also for the in vivo DMRS data. Two groups of resonances appeared in the DMR phantom spectrum, including a large water peak (natural abundance, set at 4.8 ppm) and a small glucose peak (d66, 3.8 ppm) (Figure 3(a) , upper panel). Calculation based on the fitted spectrum (Figure 3 (a)lower panel) predicted a deuterated glucose (d66) concentration of 5.2 mM in the phantom solution (close to the known value of 5 mM), which indicates the accuracy and reliability of the quantification method. As shown in Figure 3 (b) to (f), besides the large water peak (4.8 ppm), three additional well-resolved resonance signals (glucose at 3.8 ppm, Glx at 2.4 ppm and lactate at 1.4 ppm) were detected in the rat brain following the brief (2 min) infusion of d66. Excellent SNR and resonance separation in the in vivo DMR spectra acquired within 15 s per spectrum made it possible to monitor the dynamic changes of water, glucose and Glx robustly. Figure S3 illustrated the traces of 2 H signal changes in cerebral glucose, Glx and water signals from the stack-plot of original spectra obtained under isoflurane or morphine condition, respectively. Figure 4 shows the time courses of deuterated glucose and labeled Glx concentrations measured from a representative rat brain under each condition. The rates of cerebral glucose consumption and labeled Glx accumulation were found significantly increased in the morphine group when compared with the isoflurane control. Delayed Glx labeling appearance and the onset of cerebral glucose decay were also observed in the isoflurane group. All of these observations indicate an accelerated glucose metabolism with increased CMR glc and V TCA under morphine condition. Increased heart rate (416 AE 22 vs. 340 AE 20 bpm using isoflurane, p < 0.05) and mean blood pressure (141 AE 12 vs. 111 AE 12 mmHg using isoflurane, p < 0.05) were also found in the morphine group. Nevertheless, there were no significant difference in pH ¼ 7.37 AE 0.05, pCO 2 ¼ 42.5 AE 6 mmHg and pO 2 ¼ 151 AE 38 mmHg between the two groups.
Results
The T 1 values of deuterated water, glucose (d66) and Glx measured in the rat brain in vivo were 0.36 AE 0.01 s (n ¼ 15), 0.05 AE 0.02 s (n ¼ 4) and 0.20 AE 0.05 s (n ¼ 3) (obtained in separate experiments), respectively. As a comparison, T 1 values of water and d66 in the phantom solution (pH ¼ 7.0, room temperature) were 0.45 s and 0.06 s, respectively, indicating similar T 1 values between phantom solution and in vivo brain. Figure 5 demonstrates excellent fittings of the kinetic model with the dynamic changes of labeled glucose and Glx concentrations in representative rat brains under isoflurane ( Figure 5(a) ) or morphine condition ( Figure 5(b) ). As a result of kinetic analysis, increased CMR glc (0.46 AE 0.06 vs. 0.28 AE 0.13 mmol/g/min for isoflurane, p < 0.05) and V TCA (0.96 AE 0.4 vs. 0.6 AE 0.2 mmol/g/min for isoflurane, p ¼ 0.1) were determined in the morphine treated brains (n ¼ 4 for each group). Interestingly, we also found a significant increase in the glycogen synthetic rate under the morphine condition (V y : 0.08 AE 0.02 mmol/g/min vs. 0.002 AE 0.001 mmol/g/min for isoflurane, p < 0.01), indicating an elevated glycogen synthetic activity.
Discussion and conclusion
This study demonstrates that dynamic DMRS is well suited for quantitative assessment of cerebral glucose metabolisms in vivo at high/ultrahigh field. Our results suggest that this approach is robust and reliable for detecting dynamic changes in labeled glucose, Glx and water concentrations in the rat brain with excellent spectral quality and sensitivity. When combined with metabolic modeling, fluxes through important pathways such as glycolysis and TCA cycle could be determined via kinetic analysis from the same in vivo measurement, thus, allows simultaneous quantification of CMR glc and V TCA in the brains under physiological or pathological conditions. It also provides an opportunity for in vivo study of coupling relationship between aerobic and anaerobic glucose metabolisms in the healthy brain and potential de-coupling relationship in neurological disorders, which can be examined via the ratio of the simultaneously measured CMR glc and V TCA values.
Evaluation of the in vivo DMR spectroscopy
As shown in Figure 3(b) , before the infusion of deuterated glucose (d66), a large single peak at 4.8 ppm representing natural abundance signal of deuterium water was detected reliably in the rat brain. in vivo DMR spectrum is identical to that in the 1 H-MRS (e.g. d [3,3-D2] ¼ d [3,3,3-H3] for lactate, and d [4,4- D2] ¼ d [4,4-H2] for glutamate). These findings collectively reveal that in vivo brain DMRS shares a similar chemical shift range to that of proton MRS, and this knowledge simplifies the chemical shift assignment and identification of brain metabolites detected by in vivo DMRS. Considering the measured in vivo 2 H T 1 values (0.36 s for water, 0.05 s for glucose and 0.2 s for Glx) and the 0.3 s repetition time used in this study, there were partial saturation effects on the water and Glx signals, which had been corrected in the quantification. On the other hand, the glucose (d66) with a very short T 1 value was acquired under fully relaxed condition even with a very short repetition time.
Importantly, the excellent sensitivity and temporal resolution of in vivo DMRS ensures the reliable detection of dynamic change of labeled metabolites, which revealed a significantly delayed Glx labeling (for few minutes) under isoflurane condition (see Figure 4 ). This observation may provide possible explanation on the challenges of hyperpolarized 13 C technique 33, 34 in detecting the labeling of glutamate and/or glutamine in animal brain under deep anesthesia condition. A recent study has demonstrated the feasibility for detecting the 13 C signal of 2-oxoglutarate, a TCA cycle intermediate, after infusion of hyperpolarized [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]acetate in the rat brain anesthetized with isoflurane; however, the study indicated an absence of detectable 13 C Glx intermediates in the brain. 35 The slow turnover of carbon isotope label into Glx (>2 min under 2% isoflurane, as demonstrated in Figure 4 ) makes it difficult to detect the usable hyperpolarized 13 C Glx signals within a critical time window (usually <2 min) that is limited by the T 1 relaxation time of labeled Glx in vivo. Similar technical challenge could be anticipated for the hyperpolarized 13 C application in the resting human brain since the reported CMR glc ($0.3 mmol/g/min) in the human brain 36 is almost identical to that of rat brain under 2% isoflurane anesthesia condition (0.28 mmol/g/min) as measured in the present study. Nevertheless, it is interesting to see if the hyperpolarized 13 C MRS technique enables detection of the hyperpolarized 13 C Glx signal change, thus, assessment of TCA cycle metabolic activity in the human visual cortex during visual stimulation, in which an approximately 50% increase of CMR glc can be expected. 35, 36 Validity of dynamic DMRS for assessing cerebral glucose metabolisms A simplified model consisting of mass and isotope balance equations (see details in Materials and methods and Figure 2 ) written for individual metabolites were developed in this study. Several model assumptions were made for performing the kinetic analysis: (i) glucose and its isotope (d66) shared same mechanism and property for transportation, which was described by the symmetric Michaelis-Menten model; (ii) small pools of glycolytic and TCA cycle intermediates were assumed to have negligible concentrations; 4 (iii) metabolites in rapid chemical and isotopic exchange were assumed to be in equilibrium and represented by a single kinetic pool with the size equals the sum of its constituents (e.g. pyruvate and lactate); 4 (iv) glucose (d66) was the only 2 H-labeling source for TCA cycle and gluconeogenesis was negligible; (v) glutamate and glutamine were treated as a combined pool, since their resonance signals could not be differentiated robustly in the 2 H spectra; (vi) exchanges of a-ketoglutarate and glutamate in their mitochondrial and cytosolic pools were represented as a single exchange reaction. 37 When comparing with the brains under deeper anesthesia condition (2% isoflurane), kinetic analysis predicted significant increases of CMR glc (0.46 vs. 0.28 mmol/g/min) and V TCA (0.96 vs. 0.6 mmol/g/min) for the morphine-treated brains (also see an example in Figure 5 ). These increases in metabolic fluxes reflect elevated glucose metabolism at a corresponding higher level of neuronal activity under the constant morphine infusion. The values of CMR glc and V TCA reported herein are in agreement with the previous results obtained from in vivo 13 C or 1 H MRS studies under similar ($2%) isoflurane anesthetic condition; 5, 28 however, the measured CMR glc value in the present study is relatively lower than of $0.5 mmol/g/min reported from other studies under lighter anesthetic condition using 1.5% isoflurane, [38] [39] [40] suggesting that CMR glc is sensitive to the isoflurane dose or brain anesthetic level. However, the partial volume effect and very low glucose metabolism activity in the muscle surrounding the rat brain could also attribute a lower CMR glc value, since a RF surface coil was applied to collect the DMRS data without using other localization technique in the present study.
The V TCA values measured in healthy brains under two anesthesia conditions in this study were approximately two times of the CMR glc values, which are consistent with the stoichiometric relationship that one glucose is converted to two pyruvates before entering the TCA cycle. Moreover, model simulations demonstrated that major metabolic fluxes of CMR glc and V TCA are not sensitive to other parameters, fluxes and pool sizes of the intermediates (see Table S1 ). These results confirm the validity and robustness of the in vivo DMRS approach for assessing and quantifying cerebral glucose metabolisms.
Methodology comparison of DMRS and 13 C MRS for studying brain glucose metabolisms
In terms of the methodology, there is similarity between in vivo DMRS and 13 C MRS approaches for monitoring and quantifying the dynamics of isotope labeling on intermediates following the introduction of isotopelabeled glucose. There are two ways in detecting 13 Clabeled intermediates: 1,6 one based on direct 13 C detection incorporated with 1 H NOE enhancement and decoupling [2] [3] [4] [5] or with the DEPT (distortionless enhancement by polarization transfer) technique, 41, 42 and another based on the indirect 1 H detection using the proton-observer-carbon-editing (POCE) technique to specifically measure the protons attached to the 13 Clabeled carbon. [43] [44] [45] We discuss and compare the similarity and differences between in vivo DMRS and 13 C MRS methods.
T 1 relaxation and sensitivity. The dipole-dipole relaxation of 13 C spins detected by 13 C MRS or 1 H spins detected by POCE leads to long T 1 values usually in a range of >1.4 s. 46, 47 In contrast, the much shorter 2 H T 1 relaxation times of deuterated metabolites (e.g. 0.05 AE 0.02 s for d66) dominated by quadrupolar relaxation should provide a substantial sensitivity gain (e.g. >5 folds for d66, since SNR is inversely proportional to the square root of T 1 ) for the in vivo DMRS detection via more signal averaging within the same sampling time. Practically, the DMRS SNR can be further improved by using a shorter repetition time and Ernst flip angle, if the correction of saturation for water and Glx is performed based on their known T 1 values for quantification. Nevertheless, it is interesting and critical to quantitatively compare the sensitivity of DMRS versus direct 13 C and indirect POCE approaches for in vivo assessment of cerebral glucose metabolisms in future using the similar SNR quantification methods as reported in the literature. [48] [49] [50] Similarity and differences in spectral features and MRS technology. Comparing to the 13 C MRS or 1 H POCE, in vivo DMRS has the advantage of a narrower chemical shift range (in Hz unit) and a ''clean'' spectral background. The 13 C resonances of biological interest cover a very wide chemical shift range up to 200 ppm, 6 which is approximately 10 times (in Hz unit) of that 1 H MRS ($5 ppm covering from 1 ppm to 6 ppm) considering 4 times lower 13 C gyromagnetic ratio (g) than 1 H. This poses two challenges for in vivo 13 C MRS applications: a large chemical shift displacement error to localize 13 C NMR signals, especially at high and ultrahigh fields; and difficulty to achieve effective bandwidth of RF pulse excitation or refocusing covering the entire 13 C chemical shift range. In contrast, DMRS has a similar chemical shift range of interest (1-5 ppm) as 1 H MRS, however, is almost seven times narrower (in Hz) than that of 1 H-based POCE method or 13 C DEPT method based on 1 H localization because of a very low 2 H g, or 70 times narrower than that of 13 C. This advantage results in minimal chemical shift displacement for spectral localization using the slice-selection gradients and optimal performance of RF pulses.
One technical hurdle commonly faced by 13 C MRS or 1 H-based POCE is the contamination of intense macromolecule or lipid signals from subcutaneous fat, as well as the tissue water signal in 1 H-based POCE detection, thus, it requires advanced water and outvolume suppression techniques adding more RF pulses and gradients for obtaining high quality spectra. It becomes a daunting challenge to achieve threedimensional 13 C MRS imaging covering the entire brain with completely suppressed lipid or water signals. In contrast, the very low natural abundance of 2 H (73 times lower than that of 1.1% for 13 C) could limit the background 2 H signals from macromolecule contamination down to the noise level as demonstrated by global brain 2 H spectra in Figure 3 , resulting in ''clean'' spectral background. Moreover, the sole resonance detected in the baseline 2 H spectra before d66 infusion is from tissue water signal, which can serve as an internal reference for calibrating and quantifying the concentrations of 2 H-labeled glucose and intermediates and their dynamic changes (see Figures 4 and 5) , and the metabolic rates. 13 C MRS, 13 C-based DEPT or 1 H-based POCE requires dual 1 H-13 C RF channels for performing NOE and/or decoupling (in either 1 H or 13 C frequency) using a large RF power during FID acquisition, potentially leading to high specific absorption rate (SAR) of RF power: a safety concern. In addition, multiple bandpass filters are needed to isolate the cross interaction of RF power and noise between the 1 H and 13 C channels. In contrast, DMRS relies on a single channel of RF system without the need of water suppression or out volume suppression RF pulses, thus, minimizing the RF pulse number, RF power usage and SAR. These advantages make DMRS simple, robust and reliable for implementation, quantification and spatial localization based on single voxel or whole brain chemical shift imaging.
Isotope labeling pathway, metabolic modeling and quantification. One major merit of 13 C MRS is the well-resolved 13 C resonances including homonuclear J-coupling peaks and it provides rich information for performing kinetic analysis and model fitting. In contrast, DMRS has relatively poor spectral resolution and is not robust to resolve the Glu and Gln resonances; thus, it is difficult to determine the Glu-Gln transmission cycling rate.
Although the glucose metabolism pathways are identical between the 2 H-labeled glucose (e.g. d66 herein) and 13 C-labeled glucose, the fate of isotope labeling and detectable intermediates are similar but not identical in these two approaches. For instance, [1-13 C]glucose is commonly employed for in vivo 13 C studies in the literature; however, either aor b-D-[1-13 C]glucose resonance peak detected by POCE overlaps with intense water resonance or its residual, making them difficult to be reliably detected or quantified. It is equally difficult for 13 C MRS detection due to a large chemical shift difference between [1-13 C]glucose and 13 C-labeled Glx resonances. In contrast, the 2 H resonances of d66 glucose (at around 3.8 ppm) separate from the water resonance by nearly 1 ppm, thus, can be easily resolved as shown in Figure 3 .
Considering the glycolysis and TCA cycle pathways, the metabolism of 13 C-labeled glucose will label Glx C4 first, then label other carbons after multiple turns of TCA cycling, and thus sophisticated modeling approaches are critical to account the complex labeling and dynamics for determining the metabolic rates of interest. 32, [51] [52] [53] On the other hand, when the 2 H-labeled glucose (d66) enters the TCA cycle, it will replace the protons attached on Glx C4 via the a-ketoglutarate/Glx exchange; however, other 2 H labels will depart from the TCA cycle intermediates and become water (see Figure 1 ), and thus will not enter next-turn of TCA cycles. Therefore, DMRS with d66 infusion only labels Glx on the C4 position, and makes the modeling relatively straightforward and simpler than the 13 C modeling.
Accumulation of labeled water was clearly demonstrated in Figures 3 and S3 under both isoflurane and morphine conditions. This nascent mitochondrial water formation is partially associated with TCA cycle and oxygen consumption. Unfortunately, due to the complexity of the fate in deuterium label departing from the TCA cycle intermediates (or labeling dilution), we were unable to use the dynamic information of 2 H water signal, though with excellent SNR, for quantitative determination of cerebral metabolic rate of oxygen consumption without the knowledge of labeling dilution. This requires further investigation.
To simplify measurement and quantification, traditional 13 C studies commonly use a clamp protocol for introducing 13 C-labeled glucose into venous blood stream, thus, keeping a constant level of 13 C-labeled glucose in plasma during hours of 13 C MRS measurement. In this study, we employed a brief (few minutes) d66 infusion protocol, 28 resulting in large dynamics of d66 glucose signal change in brain (Figures 3 to 5) , which is critical for modeling and determination of CMR glc , V TAC and V y simultaneously. Such a protocol should be suitable for translational application in patients.
Potential, limitation and future direction of dynamic DMRS
Besides the dynamic changes of the labeled glucose and Glx, valuable information provided by the in vivo DMR spectra also involves the labeling dynamics of lactate (Figure 3 ). In this study, the resonance signal of lactate remained as a small peak in the entire duration of the DMRS experiment (Figure 3 (c) to (f)). Due to its relatively poor SNR resulting from the low in vivo concentration of 2 H labeling and low activity of anaerobic glucose metabolism in the healthy brain, the quantification of cellular lactate labeling in this study was not robust for in vivo 2 H MRS with a temporal resolution of 15 s. However, if adequate SNR becomes available (such as in the case of brain ischemia or tumor with an elevated lactate level) and the lactate pool is considered in the quantification model, simultaneous quantification of lactate production, CMR glc and V TCA would be possible.
Since the in vivo dynamic DMRS was unable to separate the labeling signals between glutamate and glutamine, a combined pool was applied in the kinetic modeling. Also for simplification, the model used in this work was a lumped one. Therefore, unlike 13 C MRS, the rate of glutamate-glutamine cycle could not be determined.
Although the present study was performed at ultrahigh field of 16.4 T, the applications of dynamic DMRS could be extended to lower field strength in animal and human brains or other tissue/organs. Furthermore, the excellent spectral quality and sensitivity of the dynamic 2 H spectra should become feasible for in vivo application using localized DMRS or imaging methods, and thus, has the potential to assess regional CMR glc and V TCA in the brain.
One unanswered question is: if the in vivo DMRS approach described herein could offer significantly higher sensitivity or better SNR than in vivo 13 C MRS methods based on either direct or indirect detection, and it deserves rigorous investigation.
In conclusion, the results of this work indicate that in vivo DMRS approach is feasible, robust and reliable for noninvasively assessing the cerebral glucose metabolisms. This novel approach provides an alternative to the established 13 C MRS methods for in vivo study of metabolic coupling relationship between aerobic and anaerobic glucose metabolisms and neuro-metabolic coupling in the animal and human brains under physiopathological condition.
